Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
RBC Capital on Acadia Pharmaceuticals (ACAD): 'We see a -1-2% stock move off the Nuplazid slight miss for 1Q23'
May 8, 2023 4:39 PM EDTRBC Capital analyst Gregory Renza reiterated an Outperform rating and $27.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).
The analyst comments "Potential stock impact & bottom line: We see a -1-2% stock move off the Nuplazid slight miss for 1Q23, reiterated FY23 revenue guidance, offset by optimism around Daybue launch... More
